Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Research from Korea Institute of Toxicology yields new findings on cancer therapy
March 2nd, 2007
Research findings, "Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring," are discussed in a new report. "CKD-602 is a camptothecin anticancer agent that was recently developed by the Chong Kun Dang Pharmaceutical Co. (Seoul, Korea). This study examined the potential adverse effects of CKD-602 on pregnancy, delivery, and lactation in female Sprague-Dawley rats as well as on the pre-and postnatal development of their offspring," scientists in South Korea report. "One hundred pregnant females were divided into four groups: three treatment groups and a control group. CKD-602 was...
Source: Drug Week (2007-03-02)
|
